Daniel Huang, MD
Hematology & Oncology · Santa Ana, CANPI 1154427920
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $37,316 of the $41,550 with a category attached, or 89.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $7,957, 2.4 times the $3,341 reported in 2019.
Across 1,866 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Johnson & Johnson$3K
- AstraZeneca$3K
- E.r. Squibb & Sons, L.L.C.$2K
- Eisai Inc.$2K
- Incyte Corporation$2K
- plus $25K from 54 others
Across 110 payments — averaging $3141.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$175K
- Incyte Corporation$45K
- Puma Biotechnology, Inc.$37K
- AstraZeneca$32K
- Boehringer Ingelheim International GmbH$15K
- Clovis Oncology, Inc.$13K
- plus $29K from 5 others
What the payments were for
- Consulting fees$1,3203%
- Food & beverage$37,31690%
- Education$1,1353%
- Other$1,7804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,550 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 41 | $671,678 |
| ErleadaApalutamide | 26 | $352,000 |
| JakafiRuxolitinib Phosphate | 20 | $330,843 |
| KeytrudaPembrolizumab | 24 | $327,032 |
| BrukinsaZanubrutinib | 21 | $297,523 |
| ImbruvicaIbrutinib | 16 | $253,491 |
| XtandiEnzalutamide | 17 | $242,538 |
| CalquenceAcalabrutinib Maleate | 18 | $223,044 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $178,612 |
| Lenalidomide | 11 | $151,764 |
| KyprolisCarfilzomib | 13 | $102,718 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 22 | $51,466 |
| OrgovyxRelugolix | 15 | $36,145 |
| EliquisApixaban | 42 | $31,148 |
| Abiraterone Acetate | 12 | $22,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $2,507 | $894,72259 claims |
| Johnson & JohnsonErleada | $2,774 | $352,00026 claims |
| Incyte CorporationJakafi | $1,719 | $330,84320 claims |
| MerckKeytruda | $1,049 | $327,03224 claims |
| Beigene USA, Inc.Brukinsa | $419 | $297,52321 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $951 | $253,49116 claims |
| Astellas Pharma US IncXtandi | $789 | $242,53817 claims |
| NovartisMekinist | $4,727 | $178,61212 claims |
| AmgenKyprolis | $876 | $102,71813 claims |
| CSL BehringPrivigen | $351 | $51,46622 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $198 | $36,14515 claims |
| PfizerEliquis | $1,466 | $31,14842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Santa Ana
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.